June 05, 2026 Sleep Study Cutoffs May Guide Discharge Preoperative sleep study values may distinguish lower-risk children within a population for whom overnight admission is currently routine. Conexiant
June 05, 2026 Can Finerenone Alter Glomerular Disease Trajectory? A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases. Conexiant
June 03, 2026 How Many US Clinicians Come From Banned Countries? Counties with at least one clinician from a banned country were more likely to be designated primary care shortage areas. Conexiant
June 01, 2026 Can Proteomics Refine Lung Screening? Proteomic biomarkers improve short-term lung cancer risk assessment. Conexiant
May 29, 2026 FDA Expands Afrezza to Pediatric Diabetes The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data. Conexiant
May 29, 2026 FDA Monthly Preview: Key June Decisions to Watch Several FDA decisions across multiple specialties are expected this month. Conexiant
May 14, 2026 Tenecteplase Fails to Boost EVT Outcomes Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients. Conexiant
May 14, 2026 Tirofiban After Tenecteplase in Stroke Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke. Conexiant
May 13, 2026 AI Discharge Summaries Show Low Harm Risk Most reviewed summaries were rated as posing no harm risk, although omissions remained common. Conexiant
May 13, 2026 PCOS Renamed PMOS After Global Consensus International initiative reframes a common endocrine disorder around its metabolic and ovarian features rather than ovarian cysts Conexiant